TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8986585

Group type: EXPERIMENTAL
Intervention: Coculture with human oviductal cells for 24 hours before embryo transfer
Number of subjects: 181

Group type: COMPARATOR
Intervention: Earles' balanced salt solution supplemented with 15% preovulatory serum (control)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Coculture with human oviductal cells
Number of subjects: 181
Study: 1575130

Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail system
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail system as a second tool after crossover
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Magnum/Magnarail group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 100
Study: 3886710

Group type: EXPERIMENTAL
Intervention: Oxaprozin
Number of subjects: 12

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 12
Study: 30500116

Group type: EXPERIMENTAL
Intervention: Rifabutin (300 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rifampin (600 mg daily from days 20-41) with Bedaquiline (400 mg on days 1 and 29)
Number of subjects: 0
Study: 28127206

Group type: EXPERIMENTAL
Intervention: Cold Snare Polypectomy (CSP)
Number of subjects: 208

Group type: COMPARATOR
Intervention: Hot Forceps Biopsy (HFB)
Number of subjects: 208
Study: 26775256

Group type: EXPERIMENTAL
Intervention: Retrograde tibial tunnel drilling
Number of subjects: 43

Group type: COMPARATOR
Intervention: Antegrade tibial tunnel drilling
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tibial tunnel diameter ≤8mm
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tibial tunnel diameter >8mm
Number of subjects: 43
Study: 24612754

Group type: EXPERIMENTAL
Intervention: Collaborative community-based care plus facility-based care
Number of subjects: 282

Group type: COMPARATOR
Intervention: Facility-based care alone
Number of subjects: 282
Study: 23090528

Group type: EXPERIMENTAL
Intervention: Usual prenatal care for mild GDM (371 women)
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Treatment for mild GDM (397 women)
Number of subjects: 1535

Group type: EXPERIMENTAL
Intervention: Glucose intolerance (767 women)
Number of subjects: 1535
Study: 18946677

Group type: EXPERIMENTAL
Intervention: MeroGel (hyaluronan resorbable packing)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Standard non‐resorbable nasal dressing
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: MeroGel
Number of subjects: 66
Study: 17156141

Group type: EXPERIMENTAL
Intervention: Sulfate supplements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faster intestinal transit
Number of subjects: 0

Group type: COMPARATOR
Intervention: Loperamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sulfate supplements with senna
Number of subjects: 0
Study: 15860487

Group type: COMPARATOR
Intervention: Cisplatin 75 mg/m2 and etoposide 100 mg/m2 (arm A)
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Carboplatin AUC=6 mg/ml min and paclitaxel 225 mg/m2 (arm B)
Number of subjects: 369
Study: 11990269

Group type: EXPERIMENTAL
Intervention: Remifentanil by patient-controlled analgesia (PCA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intramuscular meperidine
Number of subjects: 36
Study: 10221068

Group type: EXPERIMENTAL
Intervention: bisoprolol 1.25 mg/day, progressively increased to a maximum of 10 mg/day
Number of subjects: 2647

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 2647
Study: 8919833

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v. 1 hour before induction of anaesthesia (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg i.v. 1 hour before end of surgery (Group B)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (Group C - control group)
Number of subjects: 90
Study: 2195929

Group type: EXPERIMENTAL
Intervention: Calcitonin 100 IU every other day plus 1 g of elemental calcium daily
Number of subjects: 62

Group type: COMPARATOR
Intervention: Calcium supplementation only
Number of subjects: 62
Study: 514717

Group type: EXPERIMENTAL
Intervention: Electrode temperature of 44.5 C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Electrode temperatures ranging from 43.0 to 45.0 C
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Simultaneous measurements from two electrodes with different temperatures
Number of subjects: 0
Study: 31909809

Group type: EXPERIMENTAL
Intervention: Walnut diet (WD) [57-99 g/d walnuts, 7% SFAs, 16% PUFAs (2.7% ALA), 9% MUFAs]
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Walnut diet (WD)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Oleic acid replaces ALA diet (ORAD)
Number of subjects: 34
Study: 31483451

Group type: EXPERIMENTAL
Intervention: IPSE (Individual Placement and Support with enhancements)
Number of subjects: 720

Group type: COMPARATOR
Intervention: SAU (Service as Usual)
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: IPS (Individual Placement and Support)
Number of subjects: 720

Group type: COMPARATOR
Intervention: IPS vs SAU
Number of subjects: 720

Group type: COMPARATOR
Intervention: IPSE vs SAU
Number of subjects: 720
Study: 28901889

Group type: EXPERIMENTAL
Intervention: Standardised breakfast (SB) approximately 1962 kJ
Number of subjects: 40

Group type: COMPARATOR
Intervention: No breakfast (NB)
Number of subjects: 40
Study: 26400925

Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP) injections
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 24666667

Group type: EXPERIMENTAL
Intervention: PCE
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: PCC
Number of subjects: 601

Group type: EXPERIMENTAL
Intervention: PCC + PCE
Number of subjects: 601

Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 601
Study: 21181252

Group type: EXPERIMENTAL
Intervention: Single item measure (qualitative Likert-type responses)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Multi-item measure (averaged responses across antiretrovirals)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Overall agreement between measures
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Single-item measures
Number of subjects: 53
Study: 19603474

Group type: EXPERIMENTAL
Intervention: Additional meat intake (200 g pork fillet/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Omission of meat and meat products (NOM)
Number of subjects: 14
Study: 17876463

Group type: EXPERIMENTAL
Intervention: Culling infected dogs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spraying houses and animal pens with insecticide
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Spraying houses and eliminating infected dogs
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Combination of spraying houses and animal pens, and eliminating infected dogs
Number of subjects: 34

Group type: COMPARATOR
Intervention: Only spraying houses
Number of subjects: 34
Study: 15341540

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA) and multidisciplinary intervention
Number of subjects: 739

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 739
Study: 12107516

Group type: EXPERIMENTAL
Intervention: SITA Fast (HSF)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Tendency Orientated Perimetry (TOP)
Number of subjects: 76
Study: 9828797

Group type: EXPERIMENTAL
Intervention: Axially acquired, coronally reconstructed images
Number of subjects: 52

Group type: COMPARATOR
Intervention: Coronal helical CT images
Number of subjects: 52
Study: 7815703

Group type: EXPERIMENTAL
Intervention: Midazolam 4 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Midazolam 2.5 mg
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam 0 mg
Number of subjects: 60
Study: 2573336

Group type: EXPERIMENTAL
Intervention: Arousal manipulation (unrelated aversive event - shock)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Speed of fear-reduction
Number of subjects: 40
Study: 6155338

Group type: EXPERIMENTAL
Intervention: Intranasal vaccination with cold-adapted influenza A/HK/77 (H1N1) CR 35 recombinant virus
Number of subjects: 0
Study: 31793486

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise training at 30% maximum voluntary contraction for 2 min each day for 24 consecutive days combined with lifestyle modification
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group with lifestyle modification only
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Isometric handgrip exercise training at 30% maximum voluntary contraction
Number of subjects: 400
Study: 28213205

Group type: EXPERIMENTAL
Intervention: TENS stimulation on
Number of subjects: 30

Group type: COMPARATOR
Intervention: TENS stimulation off (control)
Number of subjects: 30
Study: 25948064

Group type: EXPERIMENTAL
Intervention: Doxycycline 100 mg/day for 6 weeks
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 23949899

Group type: EXPERIMENTAL
Intervention: Mildronate injection
Number of subjects: 227

Group type: COMPARATOR
Intervention: Cinepazide injection (active-control)
Number of subjects: 227
Study: 21827439

Group type: EXPERIMENTAL
Intervention: Information form given before the pre-anaesthetic consultation
Number of subjects: 200

Group type: COMPARATOR
Intervention: No information form (control group)
Number of subjects: 200
Study: 19266829

Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT premixed with normal saline (Group A)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Propofol-MCT/LCT premixed with 20 mg lignocaine (Group B)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Propofol-LCT premixed with 20 mg lignocaine (Group C)
Number of subjects: 300
Study: 18664154

Group type: EXPERIMENTAL
Intervention: Topical 5-methyl aminolevulinate cream applied for 1 hour before red light illumination
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Topical 5-methyl aminolevulinate cream applied for 3 hours before red light illumination
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control side (no treatment)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both treatment sides
Number of subjects: 10
Study: 15355485

Group type: EXPERIMENTAL
Intervention: Topiramate (100, 200, or 400 mg/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Topiramate and Placebo
Number of subjects: 0
Study: 11171823

Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naproxen 500 mg twice daily
Number of subjects: 36
Study: 9051085

Group type: EXPERIMENTAL
Intervention: buffy coat‐depleted packed red cells
Number of subjects: 697

Group type: EXPERIMENTAL
Intervention: white cell‐reduced (filtered) packed red cells
Number of subjects: 697

Group type: COMPARATOR
Intervention: no transfusion
Number of subjects: 697
Study: 8347121

Group type: EXPERIMENTAL
Intervention: Generation of random letters task
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Articulatory suppression task
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Visuo-spatial tasks
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Self-reported worriers vs non-worriers
Number of subjects: 68
Study: 2422778

Group type: EXPERIMENTAL
Intervention: 100 mg of PPS by intramuscular (I.M.) route (group I)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of PPS by intramuscular (I.M.) route (group II)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 50 mg of PPS by subcutaneous (S.C.) route (group III)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control for groups I, II, and III)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: PPS administration
Number of subjects: 30
Study: 11152033

Group type: EXPERIMENTAL
Intervention: Rectal diclofenac 0.65-1.0 mg x kg(-1)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Paracetamol 13-20 mg x kg(-1)
Number of subjects: 80
Study: 30617465

Group type: EXPERIMENTAL
Intervention: Nitrate-rich beetroot juice shot (BRJ) (6.2 mmol NO3‐)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Nitrate-depleted placebo (PLA) (<0.004 mmol NO3‐)
Number of subjects: 12
Study: 30074112

Group type: EXPERIMENTAL
Intervention: Ticagrelor monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ticagrelor combined with aspirin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study: 27441380

Group type: EXPERIMENTAL
Intervention: Professional cyclists during the Stroop task
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Recreational cyclists during the mental exertion condition
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Professional cyclists during the mental exertion condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: Heart rate, blood lactate concentration, and RPE
Number of subjects: 20
Study: 25027552

Group type: EXPERIMENTAL
Intervention: docetaxel plus cisplatin (20mg/m2/week) with concurrent radiotherapy (54Gy in 30 fractions)
Number of subjects: 40

Group type: COMPARATOR
Intervention: docetaxel plus 5-fluorouracil with concurrent radiotherapy
Number of subjects: 40
Study: 22551208

Group type: EXPERIMENTAL
Intervention: Diflunisal, a non-steroidal anti-inflammatory drug (NSAID)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study: 20206069

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 704 mg orally twice daily (NAC group, n=15)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Aminophylline 250 mg intravenously 30 min before CAG and/or PCI (aminophylline group, n=15)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Hydration alone (control group, n=15)
Number of subjects: 45
Study: 17633369

Group type: EXPERIMENTAL
Intervention: Panlongqi Tablet (PLQ) in addition to NSAID and sulfasalazine (SSZ)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (NSAID and sulfasalazine only)
Number of subjects: 104
Study: 16055815

Group type: EXPERIMENTAL
Intervention: Integrated treatment (assertive community treatment, psychoeducational multi-family groups, social skills training)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 0
Study: 12170046

Group type: EXPERIMENTAL
Intervention: 4 mg intravenous dexamethasone
Number of subjects: 140

Group type: COMPARATOR
Intervention: 1 ml intravenous saline (Control)
Number of subjects: 140
Study: 10525023

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment based on ductal flow pattern assessment (ECHO group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional indomethacin treatment (protocol group)
Number of subjects: 0
Study: 9345399

Group type: COMPARATOR
Intervention: 6 and 12 MIU of recombinant human interferon beta (r-hIFN-beta) (Rebif) given subcutaneously three times per week for 24 months in patients with relapsing-remitting MS.
Number of subjects: 0

Group type: COMPARATOR
Intervention: 6 and 12 MIU of recombinant human interferon beta (r-hIFN-beta) (Rebif) given subcutaneously three times per week for 36 months in patients with secondary progressive MS.
Number of subjects: 0
Study: 1689934

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 50 mg daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide + Amiloride 5 mg
Number of subjects: 37
Study: 760504

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (80%)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: High fat diet (60%)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control period
Number of subjects: 6
Study: 30869971

Group type: EXPERIMENTAL
Intervention: Therapist Response Questionnaire (TRQ) responses toward dependent (anaclitic) patients
Number of subjects: 84

Group type: COMPARATOR
Intervention: Therapist Response Questionnaire (TRQ) responses toward self-critical (introjective) patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapists' responses
Number of subjects: 84

Group type: COMPARATOR
Intervention: Initial affective experiences of therapists
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Therapists' emotional reactions when patients made no therapeutic progress
Number of subjects: 84
Study: 28608791

Group type: EXPERIMENTAL
Intervention: MSM
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Heterosexuals
Number of subjects: 600
Study: 26393373

Group type: EXPERIMENTAL
Intervention: Long-term oxygen therapy (LTOT) prescribed for 15 hours per day including overnight hours
Number of subjects: 114

Group type: COMPARATOR
Intervention: Best medical therapy (BMT)
Number of subjects: 114
Study: 23417588

Group type: EXPERIMENTAL
Intervention: Postoperative troponin elevation
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Preoperative troponin level
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Postoperative cardiac complications
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 187
Study: 21636122

Group type: EXPERIMENTAL
Intervention: Dexamethasone (5 mg once a day for 4 days)
Number of subjects: 304

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 304
Study: 19715426

Group type: EXPERIMENTAL
Intervention: Warm water with plain soap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Cold water with plain soap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Warm water with antibacterial soap
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antiseptic hand wipes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Alcohol‐based handrub
Number of subjects: 10
Study: 17540594

Group type: EXPERIMENTAL
Intervention: hGH (0.05mg/kg/day) for 4 days
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (siblings)
Number of subjects: 22
Study: 15513276

Group type: EXPERIMENTAL
Intervention: AM3
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 11450887

Group type: EXPERIMENTAL
Intervention: Cefepime plus netilmicin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus amikacin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Meropenem monotherapy
Number of subjects: 73

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 73
Study: 9390662

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (5 g PO b.i.d. x 14 days -> 2 g PO b.i.d. x 7 days)
Number of subjects: 7
Study: 7970099

Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 induction therapy (0.5 mg OKT3 twice daily for 10 days)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Prednisolone/cyclosporin
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Low-dose OKT3 induction therapy
Number of subjects: 50
Study: 2885650

Group type: EXPERIMENTAL
Intervention: Standard treatment plus pulsed ultrasound given weekly
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard treatment (paste impregnated bandage and a self‐adhesive elastic bandage)
Number of subjects: 108
Study: 31748223

Group type: EXPERIMENTAL
Intervention: Induction of labour at 41 weeks
Number of subjects: 2760

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 2760
Study: 28592575

Group type: EXPERIMENTAL
Intervention: Trace element measurements (vanadium and chromium)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cystatin C (CysC) estimated glomerular filtration rate (eGFR)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Environmental exposure to chromium and vanadium
Number of subjects: 36
Study: 25725487

Group type: EXPERIMENTAL
Intervention: Food-specific inhibition (inhibition in response to unhealthy food stimuli only)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: General inhibition (inhibition not contingent on type of stimuli)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control (no inhibition)
Number of subjects: 72
Study: 23756959

Group type: EXPERIMENTAL
Intervention: New connecting tube protocol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional tube protocol
Number of subjects: 80
Study: 21303311

Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS) at a dose of 200 mcg once daily for eight weeks after RF application
Number of subjects: 50

Group type: COMPARATOR
Intervention: Radiofrequency application
Number of subjects: 50
Study: 19996505

Group type: EXPERIMENTAL
Intervention: Biochemical parameters including total cholesterol, LDL cholesterol, Apo‐B, Lp(a), triglycerides, hs‐C‐reactive protein (CRP), interleukines (IL‐1beta and IL‐6), fibrinogen, D‐dimers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HDL cholesterol, Apo‐A‐1, protein C
Number of subjects: 0
Study: 16352683

Group type: EXPERIMENTAL
Intervention: CJC-1295
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 15193471

Group type: EXPERIMENTAL
Intervention: Danazol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl CR, Ferring) every 6 weeks
Number of subjects: 40
Study: 10678137

Group type: EXPERIMENTAL
Intervention: Huperzine-A in capsules (4 capsules of Hup, each contains 50 micrograms)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Huperzine-A in tablets (4 tablets of Hup, each contains 50 micrograms)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (4 tablets of placebo in capsule group and 4 capsules of placebo in tablet group)
Number of subjects: 60
Study: 9289430

Group type: EXPERIMENTAL
Intervention: GnRH analogs
Number of subjects: 33

Group type: COMPARATOR
Intervention: Chemotherapeutics PAC and radiotherapy
Number of subjects: 33
Study: 1503068

Group type: EXPERIMENTAL
Intervention: 2 mg pyridoxine (PN)-HCl/d supplementation for mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 27 mg pyridoxine (PN)-HCl/d supplementation for mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.4 mg PN-HCl/d supplementation for infants of 2 mg/d supplemented mothers
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal vitamin B-6 intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plasma pyridoxal-5'-phosphate (PLP) concentrations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase activity in mother's milk and infant plasma
Number of subjects: 0
Study: 6299652

Group type: EXPERIMENTAL
Intervention: Ketoconazole 200 mg daily
Number of subjects: 127

Group type: COMPARATOR
Intervention: Griseofulvin 250 mg daily
Number of subjects: 127